The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

• Status: Recruiting
• Trial end date: 2027-04-22
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months. The study ends after 252 included patients completed the study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maastricht University Medical Center
• Collaborator: Zuyderland Medical Centre
• Treatments: Fluconazole

Criteria

Inclusion Criteria:

• Women of at least 18 years old

• Recurrent vulvovaginal candidiasis (At least 3 episodes of clinical symptoms during the last year)

• Clinical and microbiological diagnosis of (recurrent) vulvovaginal candidiasis at time of consultation

• Capacity to understand, consent, and comply with the trial procedures

Exclusion Criteria:

• Mixed vaginal infections

• Pregnancy or the intention to become pregnant during the study period

• Women using systemic or topical antifungal medication during the last 2 weeks prior to inclusion

• Known allergies or contra-indications for Fluconazole or honey

• Candida with resistance for Fluconazole

• Women giving breastfeeding